Roivant Sciences Ltd. announces resignation and replacement of Arbutus’ entire Board

Goodmans LLP acted for Roivant Sciences Ltd. in connection with its successful removal and replacement of all members of the Board of Directors of Arbutus Biopharma Corporation (or the “Board”).

On February 24, 2025, Arbutus’ entire Board resigned from their positions as directors.

In connection with their resignations, the Board of Directors have reduced the number of directors from seven to five and replaced Arbutus’ Board with five new members, three of whom are employees of Roivant’s subsidiary, Roivant Sciences, Inc.

The newly appointed directors, including Roivant CEO Matthew Gline, will serve until the 2025 Annual General Meeting of Shareholders or until the appointment of their respective successors.

Roivant Sciences Ltd. is a U.S. multinational biopharmaceutical company and beneficially owns and controls 20.5% of Arbutus’ common shares.